Testing EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / September 16, 2026 / Levi & Korsinsky, LLP alerts investors in Embecta Corp. (NASDAQ:EMBC) that a securities class action was filed on behalf of shareholders who purchased securities between November 25, 2025 and May 4, 2026. Find out what your EMBC losses may be worth. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
EMBC closed at $9.25 per share on May 4, 2026 and closed at $3.90 on May 5, 2026, a one-session loss of $5.35 per share, or 57.8%. Full-year fiscal 2026 revenue guidance was reduced by $75 million and adjusted diluted EPS guidance was cut from $2.80 to $3.00 down to $1.55 to $1.75. The lead plaintiff deadline is August 17, 2026.
Initial Analyst Optimism
Sell-side coverage through early 2026 indicated confidence in the fiscal 2026 framework Embecta presented in November 2025 and reaffirmed in February 2026. Analysts noted the apparent durability of the pen needle franchise, a position management publicly endorsed at the J.P. Morgan Healthcare Conference in January 2026.
The Downgrades Begin
Coverage reversed within hours of the May 5, 2026 second quarter report. BTIG downgraded Embecta to Neutral from Buy, describing a "major miss" and "guidance cut." Wolfe Research followed on May 6, 2026, lowering estimates on U.S. underperformance and pointing to pen needle share loss and "overall market volume softness" as the drivers.
Analyst Coverage Timeline
Why Analyst Shifts Matter for Investors
Pen needles accounted for roughly 70% of the $75 million guidance reduction, or approximately $53 million, with an estimated $25 million tied to share loss at a single major customer and approximately $20 million to market volume softness. The lawsuit contends those U.S. dynamics were developing while guidance was being reaffirmed.
"When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. Coverage indicated confidence in Embecta's reaffirmed fiscal 2026 targets just weeks before a $75 million revenue guidance reduction, and the complaint contends the underlying U.S. share loss was already taking hold." -- Joseph E. Levi, Esq.
LEAD PLAINTIFF DEADLINE: August 17, 2026
Request a no-cost review of your EMBC trading losses or contact Joseph E. Levi, Esq. at (212) 363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Frequently Asked Questions About the EMBC Lawsuit
Q: Who is eligible to join the EMBC investor lawsuit? A: Investors who purchased EMBC stock or securities between November 25, 2025 and May 4, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.
Q: How much did EMBC stock drop? A: Shares fell approximately 57.8%, a decline of $5.35 per share, after the company disclosed second quarter fiscal 2026 revenue down 14.4% year over year, a miss against quarterly guidance, and a $75 million reduction to full-year revenue guidance driven by U.S. pen needle share loss and market volume softness. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.
Q: What is the EMBC lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 17, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: What do EMBC investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.
Q: What if I already sold my EMBC shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP